Related Experiment Video
Updated: Mar 31, 2026
07:29
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
11.4K
Pulmonary hypertension in polymyositis.
Han Wang1, Tao Liu2, Ying-ying Cai3
1Cardiovascular Disease Research Institute, The Third People's Hospital of Chengdu, 82 Qinlong St, Chengdu, Sichuan, 610031, People's Republic of China.
Clinical Rheumatology
|October 16, 2015
Summary
Pulmonary hypertension (PH) affects 16.39% of polymyositis (PM) patients, often without symptoms. Interstitial lung disease and pericardial effusion are key factors associated with PH in PM.
Area of Science:
- Cardiology
- Rheumatology
- Pulmonology
Background:
- Pulmonary hypertension (PH) is a known complication of connective tissue diseases.
- However, PH specifically in polymyositis (PM) remains understudied.
- Understanding PH prevalence and associated factors in PM is crucial for patient management.
Purpose of the Study:
- To determine the prevalence of PH in patients with polymyositis (PM).
- To identify factors associated with the development of PH in PM patients.
Main Methods:
- A multicenter study involving 61 PM patients.
- Evaluations included clinical data, physical exams, lab tests, HRCT imaging, and transthoracic echocardiography (TTE).
- PH was defined as resting systolic pulmonary artery pressure (sPAP) ≥40 mmHg, assessed via TTE.
Main Results:
- PH was identified in 16.39% of PM patients, often with minimal cardiopulmonary symptoms.
- PM patients with PH showed a higher prevalence of interstitial lung disease (ILD) and pericardial effusion (PE).
- Multivariate analysis revealed ILD and PE as independent factors associated with PH in PM (OR=8.193, p=0.029; OR=8.265, p=0.025, respectively).
Conclusions:
- The prevalence of PH in PM patients, estimated by TTE, is approximately 16.39%.
- Interstitial lung disease and pericardial effusion are significant contributors to PH development in polymyositis.
- Early detection and management of ILD and PE may be important in preventing PH in PM patients.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
870
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
870
01:14Myocarditis III: Medical Management
321
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
321
01:22Myocarditis IV: Nursing Management
359
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
359
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
4.1K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.1K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
608
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
737
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
737